Lilly Launches Phase 3 Trial for New Obesity Drug
The experimental drug EloRA TZP is now being studied in over 3,000 adults to assess its potential for long-term weight loss.
Updated on Oct. 25, 2026 in Weight Loss
Live Poll
Do you trust pharmaceutical companies to prioritize patient side effects alongside weight loss drug efficacy?
Eli Lilly has initiated phase 3 clinical trials for EloRA TZP, an experimental weight-loss drug combining turepatide and eloralintide. The drug is currently being tested in over 3,000 participants to evaluate its efficacy and safety in treating obesity and type 2 diabetes.
Why it matters
This development represents a new attempt to achieve higher weight-loss efficacy than existing therapies by targeting multiple hormonal pathways. The manufacturer is specifically focused on optimizing dosing schedules to address tolerability challenges observed in earlier studies.
A 48-week phase 2 trial involving 367 adults demonstrated an average weight loss of 23.3% in the highest-dose combination group, compared to 14.8% for the turepatide monotherapy arm. Researchers are now conducting phase 3 trials to evaluate performance in a larger population.
The players
Eli Lilly
A pharmaceutical company specializing in metabolic health, including treatments for type 2 diabetes and obesity.
The details
EloRA TZP functions by combining two distinct biological mechanisms. Turepatide activates both GIP and GLP-1 receptors to regulate blood sugar and suppress appetite, while eloralintide mimics amylin to signal satiety and delay gastric emptying. The phase 3 program aims to refine the drug's dosing schedule to improve patient adherence, as phase 2 data showed discontinuation rates due to gastrointestinal side effects reaching up to 27% in some study arms.
Timeline
The phase 2 clinical trial was conducted over a 48-week duration.
The phase 3 trials are scheduled for completion by November 2029.
Health Landscape
This drug candidate sits at the forefront of a shift toward multi-agonist therapies for chronic metabolic management. It aims to surpass the weight-loss efficacy levels established by the development pipeline for retatrutide.
As this drug is currently in the investigational stage, it is not available for clinical use or prescription. Those interested in managing obesity or type 2 diabetes should consult their physician regarding currently approved therapies and evidence-based weight management strategies.
The takeaway
EloRA TZP combines two distinct hormonal pathways to potentially enhance weight loss results for individuals with obesity or type 2 diabetes. Patients should continue to monitor their metabolic health with their doctor and keep informed about new, evidence-based treatment options.
Further reading
For more on the current landscape of metabolic treatments, visit the Weight Loss section.
More information
Find updates on ongoing research and study status at the Clinical trials registry and status search.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you trust pharmaceutical companies to prioritize patient side effects alongside weight loss drug efficacy?
